title: A serious complication of percutaneous mitral valvuloplasty: systemic embolism. How can we decrease it? Case history.
abstract: Systemic embolism is a potential and severe complication of percutaneous balloon mitral valvuloplasty (PBMV). The incidence of systemic embolism during PBMV has been reported to be less than 5% and only 0.6% with the Inoue technique. This is less than that reported in closed commissurotomy series and about the same as in open commissurotomy. In the authors' series of 50 cases, the incidence of systemic embolism was 2% (1 case). The patient had mitral restenosis (after closed commissurotomy) with mild to moderate valvular and subvalvular calcification, and cerebral embolism occurred during the procedure. To prevent systemic embolism, the authors' standard policy was to perform transesophageal echocardiography (TEE), computed tomography, and magnetic resonance imaging before the procedure and to give heparin during the procedure and two months preceding it in cases with atrial fibrillation or with a history of previous embolism and to limit manipulation of the catheter in the left atrium. The authors believe that a close scrutiny in the selection of patients, improved technology of the dilating system, good experience with PBMV, and adequate heparinization are also of great importance in the prevention of thromboembolic complications.
authors.affiliation: Cukurova University Medical School, Department of Cardiology, Adana, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Demirtaş
authors.forename: A
authors.initials: A
authors.lastname: Usal
authors.forename: A
authors.initials: A
authors.lastname: Birand
authors.forename: M
authors.initials: M
authors.lastname: San
authors.forename: T
authors.initials: T
authors.lastname: Batyraliev
authors.forename: Z
authors.initials: Z
authors.lastname: Niyazova
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation; D002114:Calcinosis / Q000628:therapy; D006328:Cardiac Catheterization; D002404:Catheterization / Q000009:adverse effects*; D017548:Echocardiography, Transesophageal; D004617:Embolism / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D006325:Heart Atria; D006331:Heart Diseases / Q000517:prevention & control; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D002542:Intracranial Embolism and Thrombosis / Q000209:etiology / Q000517:prevention & control; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D008946:Mitral Valve Stenosis / Q000628:therapy*; D011292:Premedication; D011300:Preoperative Care; D012008:Recurrence; D013927:Thrombosis / Q000517:prevention & control; D014057:Tomography, X-Ray Computed
chemical_list: D000925:Anticoagulants; D006493:Heparin